OBJECTIVE: The aim of this study was to evaluate the impact of obstructive sleep apnea syndrome (OSAS) on B-type natriuretic peptide (BNP) and to determine the effect of nasal continuous positive airway pressure (nCPAP) treatment on BNP levels. BACKGROUND: Increased sympathetic activity, repetitive rises in blood pressure, and apnea-induced wall stress may contribute as a trigger to release BNP in OSAS. However, there is uncertainty about whether OSAS affects BNP and whether application of nasal continuous positive airway pressure (nCPAP) ventilation affects release of BNP. PATIENTS AND METHODS: A prospective study in 69 consecutive patients with suspected sleep disordered breathing referred to our sleep laboratory was conducted. OSAS was confirmed in 26 normotensive and 34 hypertensive patients and ruled out in nine normotensive patients (controls) by polysomnography (PSG). RESULTS: Baseline N-terminal fragment of BNP prohormone (NT-pro-BNP) did not differ significantly between OSAS patients (hypertensive: mean +/-SEM 60.8+/-9.9 pg/ml, normotensive: 43.2+/-6.8 pg/ml) and controls (36.5+/-8.5 pg/ml). Application of CPAP resulted in a significant decrease of NT-pro-BNP in hypertensive (60.8+/-9.9 pg/ml to 47.6+/-7.4 pg/ml, p=0.023) and normotensive OSAS (43.2+/-6.8 pg/ml to 29.6+/-5.3 pg/ml, p=0.0002). In contrast, controls showed no significant differences in NT-pro-BNP after a second PSG (36.5+/-8.5 pg/ml to 40.7+/-12.3 pg/ml, p=0.597). CONCLUSIONS: Normotensive and hypertensive OSAS was not associated with a significant elevation of NT-pro-BNP. Application of nCPAP decreased NT-pro-BNP levels significantly in normotensive and, in particular, hypertensive OSAS. These findings may provide further evidence of the potential for nCPAP to improve cardiovascular comorbidity and co-mortality in OSAS and sleep disordered breathing, in general.
OBJECTIVE: The aim of this study was to evaluate the impact of obstructive sleep apnea syndrome (OSAS) on B-type natriuretic peptide (BNP) and to determine the effect of nasal continuous positive airway pressure (nCPAP) treatment on BNP levels. BACKGROUND: Increased sympathetic activity, repetitive rises in blood pressure, and apnea-induced wall stress may contribute as a trigger to release BNP in OSAS. However, there is uncertainty about whether OSAS affects BNP and whether application of nasal continuous positive airway pressure (nCPAP) ventilation affects release of BNP. PATIENTS AND METHODS: A prospective study in 69 consecutive patients with suspected sleep disordered breathing referred to our sleep laboratory was conducted. OSAS was confirmed in 26 normotensive and 34 hypertensivepatients and ruled out in nine normotensive patients (controls) by polysomnography (PSG). RESULTS: Baseline N-terminal fragment of BNP prohormone (NT-pro-BNP) did not differ significantly between OSAS patients (hypertensive: mean +/-SEM 60.8+/-9.9 pg/ml, normotensive: 43.2+/-6.8 pg/ml) and controls (36.5+/-8.5 pg/ml). Application of CPAP resulted in a significant decrease of NT-pro-BNP in hypertensive (60.8+/-9.9 pg/ml to 47.6+/-7.4 pg/ml, p=0.023) and normotensive OSAS (43.2+/-6.8 pg/ml to 29.6+/-5.3 pg/ml, p=0.0002). In contrast, controls showed no significant differences in NT-pro-BNP after a second PSG (36.5+/-8.5 pg/ml to 40.7+/-12.3 pg/ml, p=0.597). CONCLUSIONS: Normotensive and hypertensive OSAS was not associated with a significant elevation of NT-pro-BNP. Application of nCPAP decreased NT-pro-BNP levels significantly in normotensive and, in particular, hypertensive OSAS. These findings may provide further evidence of the potential for nCPAP to improve cardiovascular comorbidity and co-mortality in OSAS and sleep disordered breathing, in general.
Authors: T Nishikimi; F Yoshihara; A Morimoto; K Ishikawa; T Ishimitsu; Y Saito; K Kangawa; H Matsuo; T Omae; H Matsuoka Journal: Hypertension Date: 1996-07 Impact factor: 10.190
Authors: Michael H Olsen; Kristian Wachtell; Christian Tuxen; Eigil Fossum; Lia E Bang; Christian Hall; Hans Ibsen; Jens Rokkedal; Richard B Devereux; Per Hildebrandt Journal: J Hypertens Date: 2004-08 Impact factor: 4.844
Authors: S Javaheri; T J Parker; J D Liming; W S Corbett; H Nishiyama; L Wexler; G A Roselle Journal: Circulation Date: 1998-06-02 Impact factor: 29.690
Authors: Ravi Kanagala; Narayana S Murali; Paul A Friedman; Naser M Ammash; Bernard J Gersh; Karla V Ballman; Abu S M Shamsuzzaman; Virend K Somers Journal: Circulation Date: 2003-05-12 Impact factor: 29.690
Authors: M Melanie Lyons; Nitin Y Bhatt; Elizabeth Kneeland-Szanto; Brendan T Keenan; Joanne Pechar; Branden Stearns; Nabil M Elkassabany; Stavros G Memtsoudis; Allan I Pack; Indira Gurubhagavatula Journal: Biomark Med Date: 2016 Impact factor: 2.851
Authors: Joshua D Gottlieb; Alan R Schwartz; Joanne Marshall; Pamela Ouyang; Linda Kern; Veena Shetty; Maria Trois; Naresh M Punjabi; Cynthia Brown; Samer S Najjar; Stephen S Gottlieb Journal: J Am Coll Cardiol Date: 2009-10-27 Impact factor: 24.094
Authors: Micha T Maeder; Peter Ammann; Hans Rickli; Otto D Schoch; Wolfgang Korte; Christoph Hürny; Jonathan Myers; Thomas Münzer Journal: Sleep Breath Date: 2008-03 Impact factor: 2.816
Authors: Olaf Oldenburg; Barbara Lamp; Klaus Freivogel; Thomas Bitter; Christoph Langer; Dieter Horstkotte Journal: Clin Res Cardiol Date: 2008-07-21 Impact factor: 5.460